| Literature DB >> 25857662 |
Seth B Coffelt1, Karin E de Visser2.
Abstract
Conventional anticancer therapies, such as chemotherapy, radiotherapy, and targeted therapy, are designed to kill cancer cells. However, the efficacy of anticancer therapies is not only determined by their direct effects on cancer cells but also by off-target effects within the host immune system. Cytotoxic treatment regimens elicit several changes in immune-related parameters including the composition, phenotype, and function of immune cells. Here we discuss the impact of innate and adaptive immune cells on the success of anticancer therapy. In this context we examine the opportunities to exploit host immune responses to boost tumor clearing, and highlight the challenges facing the treatment of advanced metastatic disease.Entities:
Keywords: adaptive immune cells; anticancer therapy; cancer; inflammation; mouse model
Mesh：
Substances：
Year: 2015 PMID： 25857662 DOI： 10.1016/j.it.2015.02.006
Source DB: PubMed Journal: Trends Immunol ISSN： 1471-4906 Impact factor: 16.687